2,794 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Bought by Quarry LP

Quarry LP bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 2,794 shares of the company’s stock, valued at approximately $40,000.

A number of other institutional investors also recently bought and sold shares of ELAN. Vanguard Group Inc. raised its holdings in Elanco Animal Health by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after acquiring an additional 467,196 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Elanco Animal Health by 4.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock worth $360,425,000 after purchasing an additional 852,281 shares during the last quarter. Ancora Advisors LLC increased its holdings in shares of Elanco Animal Health by 1.4% in the first quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company’s stock worth $173,239,000 after purchasing an additional 143,326 shares during the last quarter. Magnetar Financial LLC increased its holdings in shares of Elanco Animal Health by 61.2% in the second quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock worth $120,298,000 after purchasing an additional 3,164,350 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Elanco Animal Health by 11.3% in the second quarter. The Manufacturers Life Insurance Company now owns 5,990,546 shares of the company’s stock worth $86,444,000 after purchasing an additional 609,194 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Insider Activity at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. The trade was a 200.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. The trade was a 200.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Harrington bought 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now directly owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Piper Sandler reduced their target price on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Finally, Barclays lifted their target price on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.43.

Elanco Animal Health Trading Up 1.1 %

ELAN opened at $14.66 on Friday. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80. The stock has a 50-day moving average of $14.21 and a 200 day moving average of $15.04. The firm has a market cap of $7.24 billion, a P/E ratio of -5.53, a P/E/G ratio of 1.33 and a beta of 1.40. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.18 earnings per share. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.